Key result
New oral antithrombotic drugs, including anti-platelet agents like clopidogrel and direct thrombin inhibitors like ximelagatran, provide effective alternatives to traditional therapies for the long-term prevention and treatment of thromboembolic diseases.
This review provides a general overview of the indications and classes of new oral antithrombotic drugs for the prevention and treatment of thromboembolic diseases.
May guide antithrombotic choices cautiously; leaves open comparative efficacy versus standards pending new trials.
New oral antithrombotic drugs are currently used for several indications, but mostly for the long-term treatment or prevention of thromboembolic disease in situations such as high-risk orthopedic surgery, deep vein thrombosis and myocardial infarction. They are also used in atrial fibrillation for the prevention of stroke. This family of drugs includes anti-platelet agents, eg. ticlopidine and clopidogrel, antithrombin agents, eg. ximelagatran and several others with various mechanisms of action. Oral intake has to fulfill certain conditions regarding absorption, efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Vana Christopoulou Cokkinou (2006) conducted a review in Thromboembolic disease. New oral antithrombotic drugs was evaluated. New oral antithrombotic drugs, including anti-platelet agents like clopidogrel and direct thrombin inhibitors like ximelagatran, provide effective alternatives to traditional therapies for the long-term prevention and treatment of thromboembolic diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Atrial fibrillationMore from Hospital chronicles/Hospital Chronicles